Fig. 2: Effects of HGF/c-MET inhibition ± gemcitabine on metastasis. | British Journal of Cancer

Fig. 2: Effects of HGF/c-MET inhibition ± gemcitabine on metastasis.

From: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis

Fig. 2

Representative photomicrographs of metastatic nodules in lung, liver and mesentery, as demarcated by the arrows. The bar graph shows the analysis results that the combination of HGF-neutralising antibody + gemcitabine (Hi + G) and c-MET inhibitor + gemcitabine (Ci + G) significantly reduced the incidence of metastasis compared to IgG controls. Notably, no metastases were detected in mice treated with HGF-neutralising antibody + c-MET inhibitor + gemcitabine (triple therapy, Hi + Ci + G). No significant effect was overserved with other treatment groups. **p < 0.01, Hi + Ci + G vs. IgG or Hi + Ci; *p < 0.05, Hi + G vs. IgG or Hi + Ci; #p < 0.05 Ci + G vs. IgG; n = 6 mice per group.

Back to article page